Relmada Therapeutics Files Q1 2025 10-Q
Ticker: RLMD · Form: 10-Q · Filed: May 12, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Relmada Therapeutics filed its Q1 2025 10-Q. Financials and operations update.
AI Summary
Relmada Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is involved in the pharmaceutical preparations industry. Its principal executive offices are located in Coral Gables, Florida.
Why It Matters
This filing provides investors with an update on Relmada Therapeutics' financial performance and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- March 31, 2025 (date) — Quarterly period end date
- 20250512 (date) — Filing date
- Nevada (jurisdiction) — State of Incorporation
- 2222 Ponce de Leon Blvd. 3rd Floor, Coral Gables, FL 33134 (address) — Principal Executive Offices
FAQ
What is the filing date of this 10-Q report?
The filing date of this 10-Q report is May 12, 2025.
For what period is this quarterly report?
This quarterly report is for the period ended March 31, 2025.
What is the company's state of incorporation?
The company's state of incorporation is Nevada.
What is the address of Relmada Therapeutics' principal executive offices?
The address of Relmada Therapeutics' principal executive offices is 2222 Ponce de Leon Blvd., 3rd Floor, Coral Gables, FL 33134.
What is the SEC file number for Relmada Therapeutics?
The SEC file number for Relmada Therapeutics is 000-55347.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding RELMADA THERAPEUTICS, INC. (RLMD).